ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,156 GBX | -0.12% |
|
+7.88% | +14.68% |
| May. 02 | AstraZeneca Says Calquence Combination Improves Progression-Free Survival in Phase 3 Mantle Cell Lymphoma Trial | MT |
| May. 02 | AstraZeneca: research into respiratory diseases | CF |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
2024-05-20
- Investor Day
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
151.9
USD
Average target price
164.5
USD
Spread / Average Target
+8.29%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +14.68% | 236B | |
| +29.68% | 699B | |
| +25.07% | 571B | |
| -4.35% | 364B | |
| +17.65% | 326B | |
| +3.77% | 286B | |
| +4.71% | 198B | |
| -12.43% | 194B | |
| -3.79% | 154B | |
| -3.34% | 149B |
- Stock Market
- Equities
- AZN Stock
- News AstraZeneca PLC
- Deutsche Bank Upgrades AstraZeneca to Hold from Sell, Lifts PT
